MilliporeSigma’s large experiments on Culture Biosciences’ Cloud Bioreactor Platform delivered robust, reliable results, including significant increases in the final titer for multiple CHOZN® cell lines producing recombinant therapeutic proteins.
These results demonstrate that Culture Bioscience’s Cloud Bioreactor Platform offers customers the opportunity to maintain the quality and reliability of in-house experiments while generating results faster and with more flexibility and efficiency.
Keep control: Customers have full control of their processes.
Keep IP: All data and discoveries from customer experiments on Culture’s platform are the intellectual property of the customer.
Save time and resources: Run high-throughput parallel bioprocessing experiments quickly and without the capital expenditure and staffing required to build out or expand in-house capacity.
Scale capacity flexibly: The availability of hundreds of 250mL bioreactors and several 5L systems allows customers to scale their processes as needed.
Have real-time data access 24/7: Customers can access Culture’s Bioreactor Platform and see their data always in real-time from anywhere in the world via Console, Culture’s cloud-based web application.
Collaborate remotely: Console also provides remote access to experiments. Teams can collaborate on designing, executing, and analyzing experiments, regardless of where they are located.